Kyntra Bio stock: Maxim initiates coverage for Kyntra Bio stock at USD 35.00

Published on 10/23/2026 at 03:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Maxim set a USD 35.00 target on October 13, 2026. Kyntra Bio stock faces a Nasdaq test requiring USD 50.00 million for each threshold.

Coverage, results and listing

Maxim Group set a USD 35.00 target for Kyntra Bio on October 13, 2026.
Kyntra Bio reported negative USD 1.47 million in second-quarter 2026 revenue.
Kyntra Bio had a USD 21.1 million market capitalization as of October 22, 2026.

KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio (ISIN US31572Q8814) received a new USD 35.00 price target when Maxim Group initiated coverage on October 13, 2026, according to Investing.com. The analyst action arrived as the biotechnology company worked through a Nasdaq listing challenge and advanced two clinical programs.

Nasdaq appeal carries a 180-day window

The listing issue began with a Nasdaq notice on April 2, 2026, after Kyntra Bio failed to meet requirements including at least USD 50.00 million in total assets and USD 50.00 million in total revenue. A September 30, 2026 determination called for delisting, but the company requested a hearing.

The appeal keeps Kyntra Bio common stock listed and trading while the Nasdaq panel reviews the case. The potential extension lasts up to 180 days, according to the filed report carried by StockTitan.

What does the target mean for the pipeline?

Maxim's October 13 coverage focused on FG-3246, a phase two antibody-drug conjugate program for metastatic castration-resistant prostate cancer. A separate October 19 analysis by RTTNews said interim analysis was expected in the fourth quarter of 2026, while the company was targeting a phase three roxadustat trial in the same quarter.

The latest reported numbers show why execution matters. In the second quarter of 2026, revenue was negative USD 1.47 million, compared with USD 1.35 million in the second quarter of 2025. The company recorded net income of USD 11.97 million, while operating cash flow was negative USD 3.99 million. A transcript carried by Yahoo Finance said cash, investments and accounts receivable totaled USD 95.7 million on June 30, 2026, with a runway into 2028.

Three dated steps shaped Kyntra Bio

On April 2, 2026, Nasdaq notified Kyntra Bio about the USD 50.00 million asset and revenue thresholds. On September 30, 2026, the company received the delisting determination and sought a hearing with a potential 180-day extension. On October 13, 2026, Maxim initiated coverage with a USD 35.00 target.

Two fourth-quarter milestones

The next stated milestones are the fourth-quarter 2026 interim analysis for FG-3246 and the targeted fourth-quarter 2026 start of the phase three roxadustat trial, both described in the second-quarter earnings transcript.

Market value reflects the listing risk

Kyntra Bio had a USD 21.1 million market capitalization and a USD 4.85 to USD 11.39 52-week range as of October 22, 2026. The Nasdaq listing decision therefore remains financially relevant alongside the clinical timetable.

Kyntra Bio's primary listing is the Nasdaq Global Select Market, where the company trades under KYNB. The further course of trading is shown by the continuously updated real-time quote of Kyntra Bio stock.